Informations générales (source: ClinicalTrials.gov)
A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
Observational [Patient Registry]
Hoffmann-La Roche (Voir sur ClinicalTrials)
août 2020
décembre 2026
02 décembre 2025
WAYFIND-R is a registry that aims to capture high-quality real-world data linking
next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a
solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a
platform to support the design and conduct of clinical and epidemiological research; 2.
To develop an evidence-generation platform to better understand health outcomes and
cancer care processes; and 3. To characterize the treatments and clinical course of solid
tumor cancers in patients who have undergone NGS testing.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:23 | Contact (sur clinicalTrials) | |||
Critères
Tous
- Participant is an adult (according to the age of majority as defined by local
regulations)
- Participant is currently diagnosed with any type of solid tumour cancer, at any
stage of the disease, at the enrollment date (informed consent date)
- Participant has undergone NGS testing, no longer than 3 months prior to the
enrollment date, irrespective of the availability of test results
- Informed consent has been obtained from the participant or legally authorized
representative, as per local regulations
Exclusion Criteria:
-Participant has a prior or current diagnosis of haematological malignancy